Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
T-CELL RECEPTOR EXPRESSED BY HUMAN T-CELLS THAT RECOGNIZE PEPTIDE DERIVED FROM URLC10 OR PEPTIDE DERIVED FROM DEPDC1
Document Type and Number:
WIPO Patent Application WO/2021/060343
Kind Code:
A1
Abstract:
The present invention provides a T-cell receptor (TCR) that has URLC10- or DEPDC1-specific HLA-A24-restricted cytotoxic activity. Introducing this TCR into T cells makes it possible to produce cytotoxic T cells (CTL) that can be used to treat cancer. This TCR can also be used to monitor immune response in subjects that have been inoculated with a URLC10 or DEPDC1 peptide vaccine.

Inventors:
PARK JAE-HYUN (JP)
YAMASHITA SACHIKO (JP)
HIKICHI TETSURO (JP)
IDE NOBUYUKI (JP)
NAGIRA MORIO (JP)
DOHI KEIJI (JP)
Application Number:
PCT/JP2020/035947
Publication Date:
April 01, 2021
Filing Date:
September 24, 2020
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
ONCOTHERAPY SCIENCE INC (JP)
SHIONOGI & CO (JP)
International Classes:
A61K48/00; A61K35/17; A61K35/76; A61P35/00; C07K14/725; C12N5/0783; C12N5/10; C12N5/16; C12N15/12; C12N15/63; C12Q1/02; C12Q1/6869
Domestic Patent References:
WO2008108257A12008-09-12
Foreign References:
JP2008530975A2008-08-14
JP2010506826A2010-03-04
JP2018070540A2018-05-10
Other References:
MATSUDA T. ET AL.: "Personalized immunotherapies using onconatigen/ neoantigen-reactive TCR-engineered T cells", ANNUAL ACADEMIC GENERAL CONFERENCE JAPANESE CANCER ASSOCIATION, vol. 76, 2017, pages 837
AKATSUKA Y. ET AL: "IV. T-cell receptor-engineered T cells", NIHON NAIKA GAKKAI ZASSHI, vol. 108, no. 7, 10 July 2019 (2019-07-10), pages 1384 - 1390
KIYOTANI K. ET AL.: "TCR sequencing analysis of cancer tissues and lymph nodes in colorectal cancer patients", CANCER SCIENCE, vol. 109, no. S2, 2018, pages 1091, XP055792081
Attorney, Agent or Firm:
HARUNA, Masao et al. (JP)
Download PDF: